Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01870778 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 6,600
- Enrollment target
NCT01870778 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 6,600 participants.
The verdict
NCT01870778, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 6,600 participants
- Enrollment target
Study Summary
The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.
Interventions
- DRUG Placebo
- DRUG RLX030
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,600 participants |
| Start Date | 2013-10-02 |
| Est. Completion | 2017-02-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01870778
The ClinicalTrials.gov registry entry for NCT01870778 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 6,600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01870778 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01870778 about?
NCT01870778 is a clinical study titled "Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF". The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.
What is the current status of trial NCT01870778?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 6,600 participants. The study started on 2013-10-02. Estimated completion is 2017-02-01.
What interventions are being tested in trial NCT01870778?
The interventions under investigation include: Placebo (DRUG), RLX030 (DRUG).
Who is sponsoring clinical trial NCT01870778?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.